1. A compound having Formula 1:



(1)

a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein one or two of R_1, R_2, and R_3 may each independently be hydrogen; straight or branched chain (C_1-C_7)alkyl, in which the branched alkyl chains are allowed to also form a 3-7 member heteroalkyl or alkyl ring; (cyclo(C_3-C_6)alkyl)methyl; (C_1-C_6)alkoxy; (C_1-C_6)alkyloxy(C_1-C_6)alkoxy; or sulfonamide, and

R_1, R_2, and R_3 may each independently be

mono- or di((C_1-C_6)alkyl)amino, wherein the alkyl group may be unsubstituted, mono- di-, or tri-substituted with phenyl, (C_1-C_7)alkoxy or phenoxy, further wherein the phenyl and/or phenoxy may be unsubstituted or substituted with hydroxy, nitro, cyano, amino, halogen, straight or branched chain (C_1-C_7)alkyl or (C_1-C_6)alkoxy;

phenyl, benzyl, or heteroaryl which may be unsubstituted, mono-, di-, or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, acetyl, phenyl which may be unsubstituted or substituted with one or more of (C_1-C_7)alkyl, (C_1-C_7)alkoxy, hydroxy, nitro, oxo, cyano, amino, or halogen, (C_1-C_6)alkoxy, (C_1-C_6)alkyloxy(C_1-C_6)alkoxy, mono- or di((C_1-C_6)alkyl)amino, mono- or di((C_1-C_6)alkyl)amino(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, (C_1-C_6)alkyl which may be unsubstituted or substituted with one or more of hydroxy, nitro, oxo, cyano, amino, or halogen, or heteroaryl which may be bonded through an ether, sulfide, or oxo group;

heteroaryloxy or phenoxyphenyl where each heteroaryl or phenyl may be independently unsubstituted, mono-, di-, or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkyloxy-$(C_1\text{-}C_6)$alkoxy, mono- or di$((C_1\text{-}C_6)$alkyl)amino, or amino$(C_1\text{-}C_6)$alkyl;

4-phenyl- or 4-heteroaryl-1-piperazinyl where the phenyl or heteroaryl ring may be independently unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, sulfonamide, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkyloxy-$(C_1\text{-}C_6)$alkoxy, mono- or di$((C_1\text{-}C_6)$alkyl)amino, mono- or di$((C_1\text{-}C_6)$alkyl)amino$(C_1\text{-}C_6)$alkyl);

n is 0 or 1;

Z_1, Z_2 and Z_3 are each independently



wherein

X is C or S; and

R_4–R_{10} are independently

hydrogen;

straight or branched chain (C_1-C_6)alkyl;

phenyl or benzyl which may each independently be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, (C_1-C_6)alkyloxy-(C_1-C_6)alkoxy, mono- or di((C_1-C_6)alkyl)amino, amino(C_1-C_6)alkyl; or

heteroaryl which may be unsubstituted, mono-, di- or trisubstituted with one or more of hydroxy, nitro, cyano, amino, halogen, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, (C_1-C_6)alkyloxy-(C_1-C_6)alkoxy, mono- or di((C_1-C_6)alkyl)amino, amino(C_1-C_6)alkyl;

each m is independently 0 or 1; and

W is a monocyclic ring having the structure



2. The compound or salt according to claim 1, wherein W has the structure



3. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (2-methoxybenzyl)-[4-morpholin-4-yl-6-(4-phenoxyphenyl)-[1,3,5]triazin-2-yl]-amine.

4. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2-morpholin-4-yl-4,6-bis-(4-phenyl-piperazin-1-yl)-[1,3,5]triazine.

5. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is N,N'-bis-biphenyl-4-yl-6-morpholin-4-yl-[1,3,5]triazine-2,4-diamine.

6. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2,4-bis-(4-methoxyphenyl)-6-morpholin-4-yl-[1,3,5]triazine.

7. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2,4-bis-biphenyl-4-yl-6-morpholin-4-yl-[1,3,5]triazine.

8. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2,4-bis-[4-(4-methoxyphenyl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazine.

9. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2,4-bis-[4-(2-fluorophenyl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazine.

10. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2,4-bis-[4-(3-chlorophenyl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazine.

11. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (4-{4-[(3-chlorobenzyl)-methyl-amino]-6-[4-(piperidine-1-carbonyl)-phenyl]-[1,3,5]triazin-2-yl}-phenyl)-piperidin-1-yl-methanone.

12. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (4-{4-(3-chlorobenzylamino)-6-[4-(piperidine-1-carbonyl)-phenyl]-[1,3,5]triazin-2-yl}-phenyl)-piperidin-1-yl-methanone.

13. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (4-{4-(2-chlorobenzylamino)-6-[4-(piperidine-1-carbonyl)-phenyl]-[1,3,5]triazin-2-yl}-phenyl)-piperidin-1-yl-methanone.

14. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (4,6-di-p-cyano-[1,3,5]triazin-2-yl)-methylamine.

15. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is benzyl-(4,6-di-p-cyano-[1,3,5]triazin-2-yl)-amine.

16. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (2-chlorobenzyl)-(4,6-di-p-cyano-[1,3,5]triazin-2-yl)-amine.

17. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 1-{4-[4-(4-acetylphenyl)-6-benzylamino-[1,3,5]triazin-2-yl]-phenyl}-ethanone.

18. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 1-{4-[4-(4-acetyl-phenyl)-6-(2-chloro-benzylamino)-[1,3,5]triazin-2-yl]-phenyl}-ethanone.

19. A compound as in claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, or prodrug thereof, wherein the compound is 1-{4-[4-(4-acetylphenyl)-6-(3-chlorobenzylamino)-[1,3,5]triazin-2-yl]-phenyl}-ethanone.

20. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (4-{4-(2-chlorobenzylamino)-6-[4-(piperidine-1-carbonyl)-phenyl]-[1,3,5]triazin-2-yl}-phenyl)-piperidin-1-yl-methanone.

21. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is (4-{4-(3-chlorobenzylamino)-6-[4-(piperidine-1-carbonyl)-phenyl]-[1,3,5]triazin-2-yl}-phenyl)-piperidin-1-yl-methanone.

22. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is 2,4-bis-(5-bromo-2-methoxy-phenyl)-6-propoxy-[1,3,5]triazine.

23. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is [4,6-Bis-(5-bromo-2-methoxyphenyl)-[1,3,5]triazin-2-yl]-(2-chloro-benzyl)-amine.

24. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein the compound is [4,6-bis-(3-amino-phenyl)-[1,3,5]triazin-2-yl]-(4-chloro-benzyl)-amine.

25. A compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein in an in vitro assay of kinase modulation, the compound exhibits a IC_{50} value less than or equal to 25 micromolar.

26. A pharmaceutical composition comprising

a compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, and

at least one pharmaceutically acceptable carrier or excipient.

27. A method of treating a kinase-implicated condition in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof.

28. The method of claim 27 wherein the mammal is a human.

29. The method of claim 27 wherein the mammal is a dog or cat.

30. The method of claim 27 wherein the mammal is a livestock animal.

31. A method for identifying a kinase, comprising

contacting an organism, cell, or preparation comprising the kinase with a compound as in claim 1, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof; and

detecting modulation of an activity of the kinase.